Poster: First-in-human phase 1 trial of SRF617, a potent inhibitor of CD39 activity, as monotherapy or in combination, in patients with advanced solid tumors
European Society for Medical Oncology Immuno-Oncology Congress, December 2021
Poster: The fully human antibody SRF617 is a potent inhibitor of ecto-enzyme CD39 in vivo
Society for Immunotherapy of Cancer, November 2021
Poster: CD39 Inhibition Shapes the Transcriptional Landscape of Myeloid Cells and Induces Proinflammatory States in the CT26 Syngeneic Tumor Model
American Association for Cancer Research Annual Meeting, April 2021
Poster: SRF617, a potent enzymatic inhibitor of CD39, demonstrates single-agent activity and cooperates with various cancer therapies in both solid tumor and hematologic malignancies
American Association for Cancer Research Annual Meeting, June 2020
Poster: The fully human antibody SRF617 is a potent enzymatic inhibitor of CD39 with strong immunomodulatory activity
Society for Immunotherapy of Cancer Annual Meeting, November 2019
Presentation: Targeting the Adenosine Axis to Treat Cancer
Brisbane Immunotherapy Conference, May 2019